HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parthasarathy, K. L. Articles by Crawford, E. S. Search for Related Content PubMed PubMed Citation Articles by Parthasarathy, K. L. Articles by Crawford, E. S.

Treatment of Thyroid Carcinoma: Emphasis on High-Dose ¹³¹I Outpatient Therapy

Department of Nuclear Medicine, University at Buffalo, Buffalo, New York

There is an abundance of evidence indicating that the oral administration of sodium ^13II-iodide is of value in the management of well-differentiated thyroid cancers. The first step in the management of thyroid cancer is near-total removal of the thyroid gland. Destroying any residual functioning thyroid tissue in the neck or metastatic tissue elsewhere in the body using ¹³¹I after surgery decreases the risk of recurrence and death from well-differentiated thyroid cancers. The dosage of radioiodine used for this purpose varies among different centers. Until a few years ago, radioiodine therapy using >1.110 GBq (30 mCi) ¹³¹I required hospitalization of patients to minimize radiation exposure to others. The U.S. Nuclear Regulatory Commission (USNRC) revised Title 10 of the Code of Federal Regulations (10CFR 35.75) in 1997, allowing the release of patients immediately after ¹³¹I therapy if the total effective dose equivalent from the patient to an individual does not exceed 5 mSv (0.5 rem) in any 1 y. With this change, which became effective on May 29, 1997, a patient can be treated with a higher amount of ¹³¹I as an outpatient and leave the premises with proper instructions to keep the radiation exposure to other individuals as low as it is reasonably achievable.

The objectives of this article are to (a) briefly review the types of thyroid cancer; (b) provide an overall review of the treatment of thyroid carcinomas, follow-up of these patients, and the prognostic indicators of survival; and (c) explain the radiation safety precautions and the preventive measures that can be taken to minimize the radiation exposure of family members or helpers living with the patient and the general public at large.

Key Words: ¹³¹I therapy; radioiodine treatment; thyroid cancer; treatment of thyroid cancer

This article has been cited by other articles:

				W. Muhammad, S. Faaruq, A. Hussain, M. B. Kakakhail, S. Fatmi, and Matiullah Quantitative analysis of the factors responsible for over or under dose of 131I therapy patients of hyperthyroidism Radiat Prot Dosimetry, January 1, 2008; 128(1): 90 - 97. [Abstract] [Full Text] [PDF]

				J. Vialard-Miguel, A. Georges, J. Mazere, D. Ducassou, and J.-B. Corcuff 131I in Blood Samples: A Danger for Professionals? A Problem for Immunoassays? J. Nucl. Med. Technol., September 1, 2005; 33(3): 172 - 174. [Abstract] [Full Text] [PDF]